
Jae Yong Choi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8091718/publications.pdf Version: 2024-02-01



INE YONG CHOL

#	Article	IF	CITATIONS
1	In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Annals of Neurology, 2016, 80, 247-258.	5.3	375
2	Tau PET in Alzheimer disease and mild cognitive impairment. Neurology, 2016, 87, 375-383.	1.1	208
3	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease. JAMA Neurology, 2021, 78, 961.	9.0	148
4	Subcortical ¹⁸ Fâ€AVâ€1451 binding patterns in progressive supranuclear palsy. Movement Disorders, 2017, 32, 134-140.	3.9	109
5	Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease. JAMA Neurology, 2020, 77, 632.	9.0	80
6	Progressive Tau Accumulation in Alzheimer Disease: 2-Year Follow-up Study. Journal of Nuclear Medicine, 2019, 60, 1611-1621.	5.0	75
7	Distinct tau PET patterns in atrophyâ€defined subtypes of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 335-344.	0.8	73
8	Off-Target ¹⁸ F-AV-1451 Binding in the Basal Ganglia Correlates with Age-Related Iron Accumulation. Journal of Nuclear Medicine, 2018, 59, 117-120.	5.0	70
9	Excessive tau accumulation in the parieto-occipital cortex characterizes early-onset Alzheimer's disease. Neurobiology of Aging, 2017, 53, 103-111.	3.1	66
10	¹⁸ F-AV-1451 binds to motor-related subcortical gray and white matter in corticobasal syndrome. Neurology, 2017, 89, 1170-1178.	1.1	56
11	Distinct patterns of amyloidâ€dependent tau accumulation in Lewy body diseases. Movement Disorders, 2018, 33, 262-272.	3.9	54
12	Head to head comparison of [18F] AV-1451 and [18F] THK5351 for tau imaging in Alzheimer's disease and frontotemporal dementia. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 432-442.	6.4	51
13	Predicted sequence of cortical tau and amyloid-Î ² deposition in Alzheimer disease spectrum. Neurobiology of Aging, 2018, 68, 76-84.	3.1	39
14	Environmental enrichment enhances synaptic plasticity by internalization of striatal dopamine transporters. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 2122-2133.	4.3	31
15	Inhibition of Colony-Stimulating Factor 1 Receptor by PLX3397 Prevents Amyloid Beta Pathology and Rescues Dopaminergic Signaling in Aging 5xFAD Mice. International Journal of Molecular Sciences, 2020, 21, 5553.	4.1	30
16	Age dependency of mGluR5 availability in 5xFAD mice measured by PET. Neurobiology of Aging, 2019, 84, 208-216.	3.1	27
17	The impact of demographic, clinical, genetic, and imaging variables on tau PET status. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2245-2258.	6.4	27
18	¹⁸ Fâ€AVâ€1451 binds to putamen in multiple system atrophy. Movement Disorders, 2017, 32, 171-173.	3.9	26

Jae Yong Choi

#	Article	IF	CITATIONS
19	Evaluation of the Neuroprotective Effect of Microglial Depletion by CSF-1R Inhibition in a Parkinson's Animal Model. Molecular Imaging and Biology, 2020, 22, 1031-1042.	2.6	26
20	Aβ pathology downregulates brain mGluR5 density in a mouse model of Alzheimer. Neuropharmacology, 2018, 133, 512-517.	4.1	25
21	Feasibility of Computed Tomography-Guided Methods for Spatial Normalization of Dopamine Transporter Positron Emission Tomography Image. PLoS ONE, 2015, 10, e0132585.	2.5	25
22	Relationship between dopamine deficit and the expression of depressive behavior resulted from alteration of serotonin system. Synapse, 2015, 69, 453-460.	1.2	24
23	Temporal trajectories of in vivo tau and amyloid-β accumulation in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2879-2886.	6.4	24
24	Early Detection of A <i>β</i> Deposition in the 5xFAD Mouse by Amyloid PET. Contrast Media and Molecular Imaging, 2018, 2018, 1-7.	0.8	23
25	Evaluation of the neuroprotective effect of taurine in Alzheimer's disease using functional molecular imaging. Scientific Reports, 2020, 10, 15551.	3.3	23
26	18F-AV-1451 PET Imaging in Three Patients with Probable Cerebral Amyloid Angiopathy. Journal of Alzheimer's Disease, 2017, 57, 711-716.	2.6	18
27	Predominant subcortical accumulation of 18 F-flortaucipir binding in behavioral variant frontotemporal dementia. Neurobiology of Aging, 2018, 66, 112-121.	3.1	15
28	18F-Mefway PET Imaging of Serotonin 1A Receptors in Humans: A Comparison with 18F-FCWAY. PLoS ONE, 2015, 10, e0121342.	2.5	14
29	Effective MicroPET imaging of brain 5â€HT _{1A} receptors in rats with [¹⁸ F]MeFWAY by suppression of radioligand defluorination. Synapse, 2012, 66, 1015-1023.	1.2	13
30	Evaluation of dopamine transporters and D2 receptors in hemiparkinsonian rat brains in vivo using consecutive PET scans of [18F]FPCIT and [18F]fallypride. Applied Radiation and Isotopes, 2012, 70, 2689-2694.	1.5	13
31	Human Radiation Dosimetry of [18F]AV-1451(T807) to Detect Tau Pathology. Molecular Imaging and Biology, 2016, 18, 479-482.	2.6	13
32	Tau Accumulation in Primary Motor Cortex of Variant Alzheimer's Disease with Spastic Paraparesis. Journal of Alzheimer's Disease, 2016, 51, 671-675.	2.6	13
33	Acute physical stress induces the alteration of the serotonin 1A receptor density in the hippocampus. Synapse, 2014, 68, 363-368.	1.2	12
34	18F-flortaucipir uptake patterns in clinical subtypes of primary progressive aphasia. Neurobiology of Aging, 2019, 75, 187-197.	3.1	12
35	Preliminary PET Study of ¹⁸ F-FC119S in Normal and Alzheimer's Disease Models. Molecular Pharmaceutics, 2017, 14, 3114-3120.	4.6	10
36	The Impact of Amyloid-β or Tau on Cognitive Change in the Presence of Severe Cerebrovascular Disease. Journal of Alzheimer's Disease, 2020, 78, 573-585.	2.6	10

JAE YONG CHOI

#	Article	IF	CITATIONS
37	Tau Positron Emission Tomography Imaging in Degenerative Parkinsonisms. Journal of Movement Disorders, 2018, 11, 1-12.	1.3	9
38	Optimization of the radiosynthesis of [¹⁸ F]MEFWAY for imaging brain serotonin 1A receptors by using the GE TracerLab FX _{FNâ€Pro} module. Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 589-594.	1.0	8
39	Combined Model of Aggregation and Network Diffusion Recapitulates Alzheimer's Regional Tau-Positron Emission Tomography. Brain Connectivity, 2021, 11, 624-638.	1.7	8
40	A Computed Tomography-Based Spatial Normalization for the Analysis of [¹⁸ F] Fluorodeoxyglucose Positron Emission Tomography of the Brain. Korean Journal of Radiology, 2014, 15, 862.	3.4	7
41	Therapeutic Effects of Aripiprazole in the 5xFAD Alzheimer's Disease Mouse Model. International Journal of Molecular Sciences, 2021, 22, 9374.	4.1	7
42	Effects of hypothyroidism on serotonin 1A receptors in the rat brain. Psychopharmacology, 2018, 235, 729-736.	3.1	6
43	P-Glycoprotein, not BCRP, Limits the Brain Uptake of [18F]Mefway in Rodent Brain. Molecular Imaging and Biology, 2016, 18, 267-273.	2.6	5
44	Determination of optimal acquisition time of [18F]FCWAY PET for imaging serotonin 1A receptors in the healthy male subjects. Applied Radiation and Isotopes, 2014, 89, 141-145.	1.5	4
45	Dopaminergic neuron destruction reduces hippocampal serotonin 1A receptor uptake of trans -[18 F]Mefway. Applied Radiation and Isotopes, 2014, 94, 30-34.	1.5	4
46	[18F]FPEB and [18F]FDEGPECO comparative study of mGlu5 quantification in rodent brain. Applied Radiation and Isotopes, 2015, 98, 103-107.	1.5	4
47	Translational possibility of [¹⁸ F]Mefway to image serotonin 1A receptors in humans: Comparison with [¹⁸ F]FCWAY in rodents. Synapse, 2014, 68, 595-603.	1.2	3
48	Biodistribution and Radiation Dosimetry of [18F]Mefway in Humans. Molecular Imaging and Biology, 2016, 18, 803-806.	2.6	3
49	Optimal timing of [18 F]Mefway PET for imaging the serotonin 1A receptor in healthy male subjects. Applied Radiation and Isotopes, 2016, 107, 127-132.	1.5	3
50	Preparing a ⁶⁸ Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis. Journal of Visualized Experiments, 2019, , .	0.3	3
51	Validation of Image Qualities of a Novel Four-Mice Bed PET System as an Oncological and Neurological Analysis Tool. Journal of Imaging, 2021, 7, 43.	3.0	3
52	Time and cost effective production of sodium [18F]fluoride using a dedicated automation module with disposable cassettes for GMP environment. Journal of Radioanalytical and Nuclear Chemistry, 2016, 309, 983-987.	1.5	2
53	P2â€⊋32: TAU Burden and Cognition in Earlyâ€Onset Versus Lateâ€Onset Alzheimer's Disease Spectrum. Alzheimer's and Dementia, 2016, 12, P711.	0.8	1
54	O4-07-04: In Vivo Cortical Spreading Pattern of TAU and Amyloid Pathology in the Alzheimer's Disease Spectrum. , 2016, 12, P349-P349.		1

Jae Yong Choi

#	Article	IF	CITATIONS
55	[P1–386]: DISTINCT TAU ACCUMULATION PATTERN IN DEMENTIA WITH LEWY BODY. Alzheimer's and Dementia, 2017, 13, P414.	0.8	1
56	Effects of Pâ€gp and Bcrp as brain efflux transporters on the uptake of [¹⁸ F]FPEB in the murine brain. Synapse, 2019, 73, e22123.	1.2	1
57	Developmental complex trauma induces the dysfunction of the amygdala-mPFC circuit in the serotonergic and dopaminergic systems. Biochemical and Biophysical Research Communications, 2022, 605, 104-110.	2.1	1
58	P3-263: TAU PET in Alzheimer'S Disease and Mild Cognitive Impairment. , 2016, 12, P933-P933.		0
59	Synthesis and Preliminary Evaluation of ⁶⁸ Gaâ€NOTAâ€Biphenyl (RGDyK) for the Quantification of Integrin α _v l² ₃ . Bulletin of the Korean Chemical Society, 2017, 38, 1415-1418.	1.9	0
60	[S2–01–04]: IN VIVO CORTICAL SPREADING OF TAU AND AMYLOID. Alzheimer's and Dementia, 2017, 13, P54	40.8	0
61	[P1–224]: ¹⁸ Fâ€AV1451 PET IMAGING IN SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P329.	0.8	0
62	[P2–346]: EXCESSIVE NEOCORTICAL TAU ACCUMULATION IN DOWN SYNDROME. Alzheimer's and Dementia, 2017, 13, P754.	0.8	0
63	[ICâ€Pâ€179]: PRINCIPAL COMPONENT ANALYSIS OF TAU PET IN ALZHEIMER'S DISEASE AND HEALTHY ELDERLY. Alzheimer's and Dementia, 2017, 13, P133.	0.8	0
64	[P1–365]: PREDOMINANT SUBCORTICAL ¹⁸ Fâ€AVâ€1451 BINDING IN BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P399.	0.8	0
65	[P2–342]: ¹⁸ Fâ€AVâ€1451 BINDS TO THE MOTORâ€RELATED SUBCORTICAL GRAY AND WHITE № CORTICOBASAL SYNDROME. Alzheimer's and Dementia, 2017, 13, P753.	IATTER IN	0
66	P1â€382: COMPARISON OF AD PATHOLOGIES IN HYPERTENSIVE SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT AND CEREBRAL AMYLOID ANGIOPATHY. Alzheimer's and Dementia, 2018, 14, P445.	0.8	0
67	ICâ€Pâ€078: CLINICAL SIGNIFICANCE OF A/T/N SYSTEM IN SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT PATIENTS. Alzheimer's and Dementia, 2018, 14, P69.	0.8	0
68	P1â€383: ¹⁸ Fâ€FLORTAUCIPIR BINDING PATTERNS IN CLINICAL SUBTYPES OF PRIMARY PROGRESSINA APHASIA. Alzheimer's and Dementia, 2018, 14, P446.	1E.8	0
69	ICâ€Pâ€164: MEDIAL TEMPORAL TAU CAN BE A PREDICTOR OF AMYLOIDâ€POSITIVITY IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2019, 15, P130.	0.8	0
70	ICâ€Pâ€163: TEMPORAL TRAJECTORIES OF IN VIVO TAU AND AMYLOIDâ€Î² ACCUMULATION IN ALZHEIMER'S DIS Alzheimer's and Dementia, 2019, 15, P130.	EASE.	0
71	Effect of Short-Term LTE RF-EMF Exposure on Dopamine Signaling and Behaviors in Mice. The Journal of Korean Institute of Electromagnetic Engineering and Science, 2020, 31, 847-850.	0.3	0
			_